Prostatype Genomics AB (publ) has in collaboration with Akademiska University Hospital during 2023 initiated a comprehensive study in patients with localized prostate cancer over the course of 25 years. The study has been submitted to the prestigious and largest urology conference in Europe, the 39th Annual EAU (European Association of Urology) Congress. The congress received 5651 abstracts of various kinds, the highest number in many years.

The company announced that the new study from Akademiska University Hospital has been selected to present at the EAU Congress in Paris in May, 2024. The interim results, after having analyzed approximately 100 patients out of a total cohort of approximately 500 patients, indicates that the usage of Prostatype® can aid clinicians and patients to make decisions on surveillance versus treatment, rather than having to rely on clinical indicators alone. The results reveals that the test provides an accurate assessment of the risk of long-term prostate cancer-specific mortality, or PCSM, for patients with localized prostate cancer.

These 25-year findings suggest that Prostatype® can be used as an indicator of long-term risk of prostate cancer-specific mortality. In the study, researchers at the Akademiska University Hospital analyzes the association between the Prostatype®-result and long-term oncological outcomes following radical prostatectomy in a stratified cohort sample of 500 patients who were treated between 1991 and 2001. The study is expected to be fully completed during the final quarter of 2024.

The company is anticipating that the study will be published in a scientific journal later next year which will help to expand the fields of usage of Prostatype® and its recommendation by the American NCCN and the European EAU guidelines for men who've been diagnosed with very low-, low-, or intermediate-risk disease, to determine whether their disease can be conservatively managed through active surveillance rather than treated with definitive surgery or radiation therapy.